Akari Therapeutics(DE:CLA1)
€0.060.00 (0.00%)
DE:CLA1
Akari Therapeutics financials statements
€0.06
At close:0.00 (0.00%)
Akari Therapeutics (CLA1) Ratios
0 Followers
Akari Therapeutics Ratios
DE:CLA1's free cash flow for Q2 2026 was $-3.11M. For the 2026 fiscal year, DE:CLA1's free cash flow was increased by $0.00 and operating cash flow was $-3.11M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.44 | 0.15 | 0.95 | 1.15 | 1.91 |
| Quick Ratio | 0.44 | 0.15 | 0.95 | 1.15 | 1.91 |
| Cash Ratio | 0.42 | 0.13 | 0.84 | 1.10 | 1.54 |
| Solvency Ratio | -0.88 | -0.70 | -2.18 | -1.47 | -2.86 |
| Operating Cash Flow Ratio | -0.86 | -0.63 | -3.58 | -1.79 | -3.09 |
| Short-Term Operating Cash Flow Coverage | -14.02 | -3.85 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -14.10M | $ -25.38M | $ -243.00K | $ 1.77M | $ 5.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.06 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.03 | 0.15 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.03 | 0.13 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.69 | 2.27 | -19.02 | 7.72 | 2.10 |
| Debt Service Coverage Ratio | -9.60 | -6.48 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -18.20 | 88.70 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 3.10 | 11.19 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 80.94 | 505.02 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.26 | -0.03 | 0.23 | 0.57 | 0.54 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 94.52% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 105.94% | 91.44% | 59.55% | 76.87% | 101.22% |
| Return on Assets (ROA) | -36.12% | -39.14% | -229.80% | -128.31% | -149.59% |
| Return on Equity (ROE) | -61.06% | -89.03% | 4370.31% | -990.95% | -313.69% |
| Return on Capital Employed (ROCE) | -48.61% | -70.61% | 7338.86% | -1289.11% | -309.91% |
| Return on Invested Capital (ROIC) | -44.99% | -63.82% | 7338.86% | -1289.11% | -309.91% |
| Return on Tangible Assets | -316.70% | -670.43% | -230.55% | -128.47% | -149.88% |
| Earnings Yield | -7112.00% | -6790.91% | -65536.80% | -60481.99% | -27063.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -502.28 | -2101.81 | -3357.24 | -6888.49 | -8781.94 |
| Free Cash Flow Per Share | -502.28 | -2101.81 | -3357.24 | -6888.49 | -8781.94 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -14.02 | -3.85 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -4344.99% | -4306.98% | -107603.99% | -73281.76% | -29273.12% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.01 | 0.01 | -0.07 | 0.02 | 0.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.02 | -0.02 | -0.00 | -0.00 | -0.00 |
| Price-to-Operating Cash Flow Ratio | -0.02 | -0.02 | -0.00 | -0.00 | -0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | 0.24 | -0.05 | 0.23 | 0.57 | 0.54 |
| Enterprise Value | -4.21M | 952.43K | -3.83M | -13.22M | -9.30M |
| EV to EBITDA | 0.24 | -0.05 | 0.23 | 0.57 | 0.54 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.40 | -0.08 | 0.23 | 0.61 | 0.49 |
| EV to Operating Cash Flow | 0.40 | -0.08 | 0.23 | 0.61 | 0.49 |
| Tangible Book Value Per Share | -670.25 | -4250.00 | -49.65 | 568.27 | 2577.59 |
| Shareholders’ Equity Per Share | 1346.39 | 3722.20 | -46.79 | 573.72 | 2588.27 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -822.15 | -3313.97 | -2044.75 | -5685.31 | -8119.19 |
| Tax Burden | 0.95 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 1.01 | 0.60 | 0.77 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.61 | 0.63 | 1.64 | 1.21 | 1.08 |
Currency in USD
